全文获取类型
收费全文 | 2594篇 |
免费 | 265篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 15篇 |
妇产科学 | 12篇 |
基础医学 | 80篇 |
口腔科学 | 11篇 |
临床医学 | 96篇 |
内科学 | 164篇 |
皮肤病学 | 10篇 |
神经病学 | 68篇 |
特种医学 | 457篇 |
外科学 | 83篇 |
综合类 | 190篇 |
预防医学 | 468篇 |
眼科学 | 3篇 |
药学 | 380篇 |
1篇 | |
中国医学 | 64篇 |
肿瘤学 | 770篇 |
出版年
2024年 | 5篇 |
2023年 | 38篇 |
2022年 | 68篇 |
2021年 | 137篇 |
2020年 | 144篇 |
2019年 | 138篇 |
2018年 | 131篇 |
2017年 | 109篇 |
2016年 | 116篇 |
2015年 | 100篇 |
2014年 | 213篇 |
2013年 | 188篇 |
2012年 | 144篇 |
2011年 | 152篇 |
2010年 | 110篇 |
2009年 | 140篇 |
2008年 | 115篇 |
2007年 | 86篇 |
2006年 | 96篇 |
2005年 | 56篇 |
2004年 | 63篇 |
2003年 | 52篇 |
2002年 | 50篇 |
2001年 | 59篇 |
2000年 | 34篇 |
1999年 | 49篇 |
1998年 | 23篇 |
1997年 | 23篇 |
1996年 | 26篇 |
1995年 | 21篇 |
1994年 | 22篇 |
1993年 | 5篇 |
1992年 | 14篇 |
1991年 | 9篇 |
1990年 | 10篇 |
1989年 | 8篇 |
1988年 | 3篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 18篇 |
1984年 | 14篇 |
1983年 | 13篇 |
1982年 | 13篇 |
1981年 | 10篇 |
1980年 | 9篇 |
1979年 | 13篇 |
1977年 | 5篇 |
1976年 | 3篇 |
1974年 | 3篇 |
1970年 | 3篇 |
排序方式: 共有2879条查询结果,搜索用时 15 毫秒
1.
《Clinical genitourinary cancer》2022,20(5):442-451
IntroductionSelective internal radiation therapy (SIRT) is a potential treatment of primary renal cell carcinoma (RCC) deemed unsuitable for conventional therapy. RESIRT is the first-in-human study to evaluate safety and feasibility of SIRT for primary RCC.Patients and MethodsPatients with RCC, unsuitable for, or who declined conventional therapy, were eligible. A single transfemoral micro-catheter administration of yttrium-90 (Y-90) resin microspheres (SIR-Spheres) was delivered super selectively via the renal artery to the tumour at intended radiation doses of 75, 100, 150, 200, 300 Gy and a final cohort with a procedural endpoint of “imminent stasis,” in a dose-escalation design. Post-SIRT follow-up was 12 months. Study endpoints included safety and toxicity 30-days and 12-months post-SIRT and tumour response (RECIST v1.1).ResultsIn total, 21 patients were enrolled, mean (SD) age was 75 (9.3) years, WHO performance status was 0 in 81%, 12 (57%) had stage 3 chronic kidney disease, and 7 (33%) had prior contralateral nephrectomy. Overall, 71% of patients completed 12 months of follow-up. Intended doses were delivered without any dose-limiting toxicity. Seventeen out of 21 (81%) patients experienced an adverse event (AE) from any cause within 30 days post-SIRT; all SIRT-related AEs were grade 1 to 2. Best overall tumour responses were partial response 1/21 (4.8%), stable disease 19/21 (90.5%) and progressive disease 1/21 (4.8%).ConclusionThis study demonstrated good tolerability of SIRT at all dose levels including “imminent stasis” in treating primary tumours in RCC patients otherwise unsuitable for conventional therapy. SIRT with Y-90 resin microspheres may be a feasible treatment option for RCC. 相似文献
2.
3.
《Drug metabolism and pharmacokinetics》2020,35(6):563-570
Minesapride is a novel 5-hydroxytryptamine 4 (5-HT4) receptor partial agonist that is expected to show efficacy in patients with irritable bowel syndrome with predominant constipation and functional constipation. An open-label study was conducted to evaluate pharmacokinetics (PK) and safety of minesapride. Japanese subjects, 12 elderly and 12 young, received a single oral dose of minesapride 40 mg/day in the fasted state. Metabolite profiles were also investigated in this clinical study and in an in vitro study using cryopreserved hepatocytes. Clinical results showed that minesapride was rapidly absorbed (Cmax: 2302.1 ng/mL in the elderly group, 2117.5 ng/mL in the young group), and the plasma concentration then decreased with half-life of approximately 7 h. There were no notable PK differences between elderly and young groups. No serious adverse events (AEs) were observed. The only AE that occurred in 2 or more subjects was diarrhea. Metabolite profiles in plasma and urine were similar between elderly and young groups. No major metabolites exceeded 10% of unchanged minesapride, and results of the in vitro study suggested that there were no human-specific metabolites. From the viewpoints of PK and metabolite profiling, no dose adjustment of minesapride is warranted in elderly population without renal or hepatic impairment. 相似文献
4.
《Radiography》2020,26(4):e195-e200
IntroductionAdverse events in radiology are quite rare, but they do occur. Radiation safety regulations and the law obligate organizations to report certain adverse events, harm and near misses, especially events related to patients' health and safety. The aim of this study was to describe and analyse incidents related to radiation safety issues reported in Finland.MethodsThe data were collected from incident reports documented by radiology personnel concerning notifications of abnormal events in medical imaging made to the Radiation and Nuclear Safety Authority between 2010 and 2017. During these eight years, 312 reports were submitted. Only events reported from radiology departments were included; nuclear medicine, radiotherapy and animal radiology cases were excluded. The final number of reports was 293 (94%).ResultsThe majority of the 293 approved reports were related to computed tomography (CT, 68.3%) and to X-ray examinations (27.6%). Altogether 82.9% of those irradiated were adults, most of whom were exposed to unnecessary radiation through CT (86.5%), 5.5% were children, and 4.4% pregnant women. The most common effective dose of unnecessary radiation was 1 mSv or less (89.7% of all examinations). The highest effective doses were reported in CT (from under 1 mSv–20 mSv and above). The reasons for the adverse events were incorrect identification (32%), incorrect procedure, site or side (30%); and human errors or errors of knowledge (20%).ConclusionAdverse events occurred especially in CT examinations. It is important to collect and analyse incident data, assess the harmful events, learn from them and aim to reduce adverse events.Implications for practiceThis study emphasizes the need for radiological personnel to obtain evidence-based information on adverse events and focus on training to improve patient safety. 相似文献
5.
6.
Haiyung Cheng Jules I. Schwartz Charles Lin Raju D. Amin James R. Seibold Kenneth C. Lasseter David L. Ebel Dominick J. Tocco J. Douglas Rogers 《Biopharmaceutics & drug disposition》1994,15(5):409-418
MK-679 (R(?)-3-((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)(3-(dimethylamino)-3-oxopropyl)thio)methyl)thio(propanoic acid) is a potent and specific LTD4-receptor antagonist. The disposition of MK-679 was investigated in a three-way crossover study in 12 healthy males receiving single intravenous doses of 75, 250, and 500 mg of MK-679. A greater than proportional increase in the area under the plasma concentration—time curve of MK-679 was observed with increase in dose. The plasma concentration data for each subject fitted well to the differential equations for a two-compartment model with linear tissue distribution and Michaelis-Menten elimination from the central compartment, indicating that the elimination of MK-679 in humans is saturable. In a previous study, the disposition of MK-679 in humans was also dose-dependent when given together with its S(+)-isomer, L-668,018. Thus, the disposition of MK-679 in humans is dose-dependent regardless of the presence of its stereoisomer. Also, the bioavailability of MK-679 was determined in six healthy males receiving simultaneously an oral dose of 250 mg of MK-679 and intravenous infusion of 1 mg 14C-MK-679. Results of this study indicate that the oral bioavailability of MK-679 is nearly quantitative. 相似文献
7.
S.L. CHARLES NGU PETER DUVAL CATHRYN COLLINS 《Journal of Medical Imaging and Radiation Oncology》1992,36(4):321-322
Management of breast cancer during pregnancy is complicated by the high risks of abortion and foetal malformation from the use of radio therapy and chemotherapy. A case of breast cancer during pregnancy, treated with radiotherapy, and the estimated foetal dose is reported. 相似文献
8.
阳江高本底地区居民健康流行病学调查数据库与统计分析方法 总被引:1,自引:0,他引:1
目的 研究应用计算机数据库技术及先进统计分析方法,对阳江高本底地区10多万人20余年的健康随访研究资料和剂量学调查资料进行储存、管理和分析。方法 通过调研和比较分析,确定采用Foxbase系列数据库管理系统按专题建立数据库,借助于ID号实现记录连接;一般统计分析由SAS完成;交叉分组人年列表由Epicure中的Datab完成;癌症相对危险分析用AMFIT程序。结果 建立了40MB的各专题研究库,主要包括:10余万人的人口学数据库(1979~1995)、1.2万人的死因数据库(1979~1995)和526个村庄6783户、5273人的剂量数据库。提出了动态群组研究资料(1979~1986)与固定群组研究资料(1987~1995)的合并方法:首选方法是建立假想的基于记录连接的以1979年为起点的(固定)群组。另一方法是将不同阶段群组研究的人年表分层直接相加。计算了每个成员基于卧室内、起居室内、室外村平均剂量率与性别-年龄别居留因子的累积剂量。完成了以性别、atainedage、随访年代及剂量交叉分组的人年列表,对癌症死亡资料(1979~1990)进行了危险分析。结论 应用计算机数据库管理系统与统计分析技术使阳江高本底地区研 相似文献
9.
近些年来对A群多糖脑膜炎菌苗最适免疫剂量进行了一系列现场流行病学及血清学效果的对比研究。首先肯定了我国生产的菌苗与法国Merieux研究所生产的苗苗在人体接种后观察一年内具有同等杀菌抗体反应。以后在严格对比下观察了国内生产的多糖菌苗接种30μg及50μg一年内的血清杀菌抗体反应。结果完全相同;而全身反应则30μg为50μg剂量的五分之一。在我国80年代流脑流行地区内确证了30μg免后人群保护率为99%与国外50μg的保护率(97.2%)相似。国内连续三年在流行地区内对比观察了30μg、与50μg的流行病学预防效果,其人群保护率相似.与国外(Reingold).的报告亦相似。最后结论是本菌苗的最适免疫剂量为30μg.不但其预防效果与50μg相同,而且菌苗反应轻微,经济效益高,有利于在发展中国家推广使用。 相似文献
10.
John M. H. de Klerk Bernard A. Zonnenberg Alfred D. van het Schip Aalt van Dijk Shiuw H. Han Jacques M. S. R. Quirijnen Geert H. Blijham Peter R van Rijk 《European journal of nuclear medicine and molecular imaging》1994,21(10):1114-1120
Rhenium-186 hydroxyethylidene diphosphonate (186Re-HEDP) has been used for the palliative treatment of metastatic bone pain. A phase 1 dose escalation study was performed using 186Re-HEDP Twenty-four patients with hormone-resistant prostate cancer entered the study. Each patient had at least four bone metastases and adequate haematological function. Groups of at least three consecutive patients were treated with doses starting at 1295 MBq and increasing to 3515 MBq (escalated in increments of 555 MBq). Thrombocytopenia proved to be the dose-limiting toxicity, while leucopenia played a minor role. Early death occurred in one patient (10 days after administration) without clear relationship to the 186Re-HEDP therapy. Transient neurological dysfunction was seen in two cases. Two patients who received 3515 MBq 186Re-HEDP showed grade 3 toxicity (thrombocytes 25–50 × 109/1), defined as unacceptable toxicity. After treatment alkaline phosphatase levels showed a transient decrease in all patients (mean: 26% ± 10% IUA; range: 11%–44%). Prostate-specific antigen values showed a decline in eight patients, preceded by a temporary increase in three patients. From this study we conclude that the maximally tolerated dose of 186Re-HEDP is 2960 MBq. A placebo-controlled comparative study on the efficacy of 186Re-HEDP has been initiated. 相似文献